As shown in Figure 5A,B, the expression levels of CypA and CD147 were reduced by treatment with C9 or CsA in a dose-dependent manner in NCI-H1650- and HCC827-derived CSCs, implying that the anticancer activities of C9 and CsA on NSCLC CSCs resulted from the downregulation of the CypA/CD147 axis. This evidence concerns the gene BSG and non-small cell lung carcinoma.